Oncolytics Biotech is positioned as a development stage biopharmaceutical company with a focus on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a cancer therapeutic that is in various clinical trials for human use. Its cancer product is a potential therapeutic for tumors possessing an activated Ras pathway. Founded in 1998, the ONCY is headquartered in Calgary, Canada.  For more information, visit the company’s website at www.oncolyticsbiotech.com